Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock Has Consensus Price Target of $30.91 According to Brokerages

Posted by Brian Himes on Nov 6th, 2026

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $30.91.

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday, September 10th. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a research note on Friday, August 21st. Mizuho upped their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Finally, Wedbush decreased their target price on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating for the company in a research note on Thursday, October 29th.

View Our Latest Stock Analysis on Bicara Therapeutics

Bicara Therapeutics Stock Down 7.9%

Shares of BCAX opened at $8.19 on Friday. The business has a 50-day simple moving average of $18.48 and a two-hundred day simple moving average of $20.99. Bicara Therapeutics has a 12-month low of $7.87 and a 12-month high of $30.99. The stock has a market cap of $541.96 million, a PE ratio of -2.64 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). On average, equities research analysts expect that Bicara Therapeutics will post -3.49 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $524,625.00. Following the transaction, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at approximately $5,082,315.18. The trade was a 9.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the transaction, the chief financial officer owned 129,855 shares in the company, valued at $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 58,750 shares of company stock valued at $1,554,800. 13.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. Sterling Capital Management LLC grew its holdings in shares of Bicara Therapeutics by 457.0% during the third quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock valued at $26,000 after buying an additional 1,138 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Bicara Therapeutics by 7.2% in the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after acquiring an additional 1,140 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Bicara Therapeutics by 15.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock worth $224,000 after acquiring an additional 1,617 shares during the last quarter. Quantinno Capital Management LP lifted its position in Bicara Therapeutics by 16.1% in the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the 3rd quarter valued at about $63,000.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.